Cell Culture Engineering

Since the introduction of recombinant human growth hormone and insulin a quarter century ago, protein therapeutics has greatly broadened the ho- zon of health care. Many patients suffering with life-threatening diseases or chronic dysfunctions, which were medically untreatable not long ago, can atte...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Autor principal: Hu, Wei-Shou
Formato: Livre numérique
Idioma:Anglais
Publicado em: Berlin, Heidelberg : Springer Berlin Heidelberg [20..].
Cham : Springer Nature
Edição:1st ed. 2006.
coleção:Advances in Biochemical Engineering/Biotechnology 101
Assuntos:
Acesso em linha:Accès sur la plateforme de l'éditeur
Accès sur la plateforme Istex
Accès Université d'Orléans
Accès INSA CVL
Nota: Archives Springer e-books (Licence nationale)
Archives Springer e-books (Licence nationale)
Autres localisations: Voir dans le Sudoc
Edition sous un autre format:• Cell culture engineering, volume editor: Wei-Shou Hu, Berlin, Springer, 2006, 1 vol. (x-168 p.), Advances in biochemical engineering/biotechnology, 3-540-34006-8
LEADER 04022nam a22003977a 4500
001 938588
008 080410q2000 xx ||| |||| 00| 0 eng d
009 PPN123134374
020 |a 9783540340072 
041 0 |a eng 
082 |a 660.6 
082 |a 540 
100 1 |a Hu, Wei-Shou. 
245 1 0 |a Cell Culture Engineering   |c edited by Wei-Shou Hu. 
250 |a 1st ed. 2006. 
260 |a Berlin, Heidelberg :  |b Springer Berlin Heidelberg. 
260 |a Cham :  |b Springer Nature,  |c [20..]. 
490 0 |a Advances in Biochemical Engineering/Biotechnology  |v 101  |x 1616-8542 
500 |a Archives Springer e-books (Licence nationale) 
500 |a Archives Springer e-books (Licence nationale) 
505 1 |a Established Bioprocesses for Producing Antibodies as a Basis for Future Planning Fedbatch Culture and Dynamic Nutrient Feeding The Push-to-Low Approach for Optimization of High-Density Perfusion Cultures of Animal Cells Towards Industrial Application of Quasi Real-Time Metabolic Flux Analysis for Mammalian Cell Culture Engineering Cells for Cell Culture Bioprocessing Physiological Fundamentals 
506 |a Accès en ligne pour les établissements français bénéficiaires des licences nationales 
506 |a Accès soumis à abonnement pour tout autre établissement 
506 |a Conditions particulières de réutilisation pour les bénéficiaires des licences nationales. https://www.licencesnationales.fr/springer-nature-ebooks-contrat-licence-ln-2017 
520 |a Since the introduction of recombinant human growth hormone and insulin a quarter century ago, protein therapeutics has greatly broadened the ho- zon of health care. Many patients suffering with life-threatening diseases or chronic dysfunctions, which were medically untreatable not long ago, can attest to the wonder these drugs have achieved. Although the ?rst generation of p- tein therapeutics was produced in recombinant Escherichia coli, most recent products use mammalian cells as production hosts. Not long after the ?rst p- duction of recombinant proteins in E. coli, it was realized that the complex tasks of most post-translational modi?cations on proteins could only be ef?ciently carried out in mammalian cells. In the 1990s, we witnessed a rapid expansion of mammalian-cell-derived protein therapeutics, chie?y antibodies. In fact, it has been nearly a decade since the market value of mammalian-cell-derived protein therapeutics surpassed that of those produced from E. coli. A common characteristic of recent antibody products is the relatively large dose required for effective therapy, demanding larger quantities for the treatment of a given disease. This, coupled with the broadening repertoire of protein drugs, has rapidly expanded the quantity needed for clinical applications. The increasing demand for protein therapeutics has not been met exclusively by construction of new manufacturing plants and increasing total volume capacity. More - portantly the productivity of cell culture processes has been driven upward by an order of magnitude in the past decade 
650 |a Cultures cellulaires 
650 |a Chimie 
650 |a Cytologie 
650 |a Biochimie 
650 |a Biotechnologie 
776 0 |0 109970691  |t Cell culture engineering  |f volume editor: Wei-Shou Hu  |c Berlin  |n Springer  |d 2006  |p 1 vol. (x-168 p.)  |s Advances in biochemical engineering/biotechnology  |z 3-540-34006-8 
856 4 |q PDF  |u https://doi.org/10.1007/11751571  |z Accès sur la plateforme de l'éditeur 
856 4 |u https://revue-sommaire.istex.fr/ark:/67375/8Q1-G5678DVK-Q  |z Accès sur la plateforme Istex 
856 4 |5 452349901:747897506  |u https://ezproxy.univ-orleans.fr/login?url=https://dx.doi.org/10.1007/11751571  |z Accès Université d'Orléans 
856 4 |5 180339901:75091050X  |u https://ezproxy.insa-cvl.fr/login?qurl=https://dx.doi.org/10.1007/11751571  |z Accès INSA CVL 
997 |0 938588  |1 Livre numérique  |a Ressource numérique  |b INSA  |b ENSA  |c 0/Bibliothèque numérique/  |c 1/Bibliothèque numérique/Autre ressource numérique/